<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12205">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00507767</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00227</org_study_id>
    <secondary_id>NCI-2009-00227</secondary_id>
    <secondary_id>CDR0000559148</secondary_id>
    <secondary_id>2006-0571</secondary_id>
    <secondary_id>7815</secondary_id>
    <secondary_id>N01CM62202</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT00507767</nct_id>
    <nct_alias>NCT00513227</nct_alias>
  </id_info>
  <brief_title>Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer</brief_title>
  <official_title>A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well dasatinib works in treating patients with head and neck
      cancer that has come back or spread to other areas of the body. Dasatinib may stop the
      growth of tumor cells by blocking some of the enzymes needed for cell growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the 12-week progression-free survival rate and the objective response rate,
      as measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, in patients
      with recurrent or metastatic squamous cell carcinoma of the head and neck treated with
      dasatinib.

      SECONDARY OBJECTIVES:

      I. To define metabolic response rate by positron emission tomography (PET) scan at 0, 8, and
      12 weeks.

      II. To define overall survival distribution from initiation of dasatinib. III. To define
      duration of response. IV. To determine if there is a correlation between clinical benefit
      from dasatinib (defined as disease response or stabilization) and pharmacokinetics,
      pharmacodynamics (phosphorylated Src [pSrc] expression in platelets), or changes in serum
      levels of cytokines, growth factors, and growth factor receptors relevant to the Src
      signaling pathway.

      V. To examine the relationship between clinical benefit and mammary tumor and squamous cell
      carcinoma-associated protein (EMS1) gene amplification and cortactin expression levels in
      tumor tissue prior to therapy and the modulation of cortactin levels by treatment.

      VI. To compare the effects of dasatinib on apoptosis by terminal deoxynucleotidyl
      transferase dUTP nick end labeling (TUNEL) assay in tumor tissues comparing pre- and
      post-treatment biopsies.

      VII. To assess the tolerability of dasatinib in this patient population. VIII. To describe
      the pharmacokinetic (PK) profile and relative bioavailability of dasatinib suspension in
      patients receiving the drug through percutaneous gastrostomy tube.

      IX. To descriptively assess safety, toxicity, and efficacy of dasatinib crushed and
      administered by feeding tube.

      OUTLINE:

      Patients receive dasatinib orally (PO) or via percutaneous gastrostomy (PEG) tube twice
      daily (BID). Courses repeat every 28 days in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed up for at least 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants With Progression-free Survival at 12-weeks</measure>
    <time_frame>At 12-weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression-free survival (PFS) is defined as stable disease or better. Participants who have received at least one dose of dasatinib and who die or leave the study before 12 weeks will be counted as having progressive disease.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma</condition>
  <condition>Recurrent Metastatic Squamous Neck Cancer With Occult Primary</condition>
  <condition>Recurrent Salivary Gland Cancer</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Hypopharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Nasopharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Recurrent Verrucous Carcinoma of the Larynx</condition>
  <condition>Recurrent Verrucous Carcinoma of the Oral Cavity</condition>
  <condition>Salivary Gland Squamous Cell Carcinoma</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Hypopharynx</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Nasopharynx</condition>
  <condition>Stage IVA Salivary Gland Cancer</condition>
  <condition>Stage IVA Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Stage IVA Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage IVA Verrucous Carcinoma of the Larynx</condition>
  <condition>Stage IVA Verrucous Carcinoma of the Oral Cavity</condition>
  <condition>Stage IVB Salivary Gland Cancer</condition>
  <condition>Stage IVB Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Stage IVB Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage IVB Verrucous Carcinoma of the Larynx</condition>
  <condition>Stage IVB Verrucous Carcinoma of the Oral Cavity</condition>
  <condition>Stage IVC Salivary Gland Cancer</condition>
  <condition>Stage IVC Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Stage IVC Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage IVC Verrucous Carcinoma of the Larynx</condition>
  <condition>Stage IVC Verrucous Carcinoma of the Oral Cavity</condition>
  <condition>Tongue Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (dasatinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive dasatinib PO or via PEG tube BID. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib</intervention_name>
    <description>Given PO or via PEG tube</description>
    <arm_group_label>Treatment (dasatinib)</arm_group_label>
    <other_name>BMS-354825</other_name>
    <other_name>Sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (dasatinib)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (dasatinib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has histologically proven squamous cell carcinoma of the head and neck that
             is recurrent after surgery and/or radiation therapy or chemoradiation therapy or is
             metastatic and disease must be measurable by RECIST criteria

          -  Patients must have measurable disease as defined by RECIST criteria

          -  Patients have received =&lt; 1 prior chemotherapeutic regimen for recurrent or
             metastatic disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Leukocytes &gt;= 3,000/mcL

          -  Absolute neutrophil count &gt;= 1,500/mcL

          -  Platelets &gt;= 100,000/mcL

          -  Hemoglobin (Hgb) &gt;= 9.0 g/dL

          -  Total bilirubin =&lt; 1.5 X upper limit of normal

          -  Albumin &gt;= 2.5 g/dL

          -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =&lt; 1.5 X upper
             limit of normal

          -  Creatinine =&lt; 3 mg/dl

          -  Paraffin embedded tumor tissue that is appropriate for immunohistochemistry (IHC) and
             fluorescent in situ hybridization (FISH) analysis must be available or patient must
             be amenable to biopsy to obtain tissue for the study

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Patient must not be pregnant or breastfeeding; all sexually active females of
             child-bearing potential and all sexually active males with sexual partners of
             child-bearing potential should practice contraception (e.g. barrier, hormonal,
             intrauterine device [IUD]) or sexual abstinence while in the study and for two months
             following completion of therapy

          -  Brain metastases permitted provided the patient does not require anticonvulsants or
             corticosteroids, or has been off them at least 7 days; patients with brain metastases
             must be either &gt; 4 weeks beyond cranial irradiation or must be felt not to require it
             at that time

          -  The patient's O2 saturation must be &gt;= 92% on room air

        Exclusion Criteria:

          -  Chemotherapy or palliative radiotherapy for recurrent and/or metastatic disease
             within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
             or failure to recover to at least grade 1 from adverse events due to agents
             administered more than 4 weeks earlier; concomitant chemoradiation therapy within 6
             weeks prior to entering the study or failure to recover to at least grade 1 from
             adverse events due to agents administered more than 4 weeks earlier

          -  Other anti-neoplastic agents, i.e., cytotoxic chemotherapy, immunotherapy,
             radiotherapy or investigational therapy, used to treat the primary disease will not
             be allowed during the study; local radiation (excluding radiotherapy to the target
             lesion) for supportive reasons involving a small radiation field may be allowed

          -  Patient has a history of uncontrolled or severe medical disease which could
             compromise participation in the study such as uncontrolled diabetes (fasting blood
             glucose &gt; 200 mg/dl), uncontrolled hypertension (systolic blood pressure [BP] &gt; 160
             or diastolic BP &gt; 100 mmHg), severe infection (bacterial infection requiring
             intravenous [IV] antibiotics or human immunodeficiency virus [HIV]), angina at rest,
             congestive heart failure New York Heart Association (NYHA) class III or IV,
             ventricular arrhythmias requiring therapy, myocardial infarction within 6 months, &gt;
             grade 2 neuropathy

          -  Patients may not be receiving any other investigational agents

          -  Patients who require concurrent treatment with any medications or substances that are
             potent inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide
             4 (CYP3A4) are ineligible; efforts should be made to switch patients with gliomas or
             brain metastases who are taking enzyme-inducing anticonvulsant agents to other
             medications

          -  Echocardiogram less than institutional normal measured by echocardiogram for subjects
             with history of congestive heart failure, symptoms of congestive heart failure,
             clinical evidence suggesting impaired cardiac function

          -  Patients may not have any clinically significant cardiovascular disease including the
             following:

               -  Myocardial infarction or ventricular tachyarrhythmia within 6 months

               -  Prolonged correct QT interval (QTc) &gt; 480 msec (Fridericia correction)

               -  Major conduction abnormality (unless a cardiac pacemaker is present)

          -  Pregnant women and women who are currently breast-feeding may not participate in this
             study; all women of childbearing potential must have a negative pregnancy test within
             72 hours prior to enrolling in the study; postmenopausal women must be amenorrheic
             for at least 12 months to be considered of non-childbearing potential

          -  Patients having pleural effusion
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vassiliki Papadimitrakopoulou</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>September 17, 2014</lastchanged_date>
  <firstreceived_date>July 26, 2007</firstreceived_date>
  <firstreceived_results_date>April 18, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Verrucous</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Laryngeal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Paranasal Sinus Neoplasms</mesh_term>
    <mesh_term>Salivary Gland Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: July 24, 2007 to February 26, 2009. Al recruitment done at The University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dasatinib</title>
          <description>100 mg orally twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dasatinib</title>
          <description>100 mg orally twice daily</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="54" spread="10" lower_limit="46" upper_limit="78"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Progression-free Survival at 12-weeks</title>
        <description>Progression-free survival (PFS) is defined as stable disease or better. Participants who have received at least one dose of dasatinib and who die or leave the study before 12 weeks will be counted as having progressive disease.</description>
        <time_frame>At 12-weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib</title>
            <description>100 mg orally twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Progression-free Survival at 12-weeks</title>
            <description>Progression-free survival (PFS) is defined as stable disease or better. Participants who have received at least one dose of dasatinib and who die or leave the study before 12 weeks will be counted as having progressive disease.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit=".2" upper_limit=".05"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment period three 4-week cycles for total of 12 weeks with follow up every 2 cycles following first cycle. Study data collection period for all participants was 18 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dasatinib</title>
          <description>100 mg orally twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Toxicity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing (without monitoring)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea/vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain (bone)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>With normal Absolute neutrophil count (ANC)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Vassiliki Papadimitrakopoulou, Professor</name_or_title>
      <organization>MD Anderson Cancer Center</organization>
      <phone>713-792-6363</phone>
      <email>vpapadim@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
